Take vedolizumab home: transition from intravenous to subcutaneous treatment
In 2020, the European Medicines Agency approved subcutaneous (SC) vedolizumab (VDZ) for the maintenance treatment of adult patients with moderate to severe inflammatory bowel disease (IBD). This article reviews the efficacy, safety, persistence, pharmacology, patient satisfaction, and economic impli...
| Hoofdauteurs: | , , , |
|---|---|
| Formaat: | Artikel |
| Taal: | English |
| Gepubliceerd in: |
SAGE Publishing
2024-05-01
|
| Reeks: | Therapeutic Advances in Chronic Disease |
| Online toegang: | https://doi.org/10.1177/20406223241247648 |